Second quarter 2023 results

Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

14:30 -16:00 CET | 8:30am – 10am EST

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Bill Sibold

Specialty Care

Olivier Charmeil

Olivier Charmeil

General Medicines

Dietmar Berger

Dietmar Berger

Global Head of R&D ad interim

Thomas Triomphe

Thomas Triomphe

Vaccines

Julie van Ongevalle

Julie van Ongevalle

Consumer Healthcare

Roy Papatheodorou

Roy Papatheodorou

General Counsel

Highlights

We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.
Paul Hudson

Paul Hudson

Chief Executive Officer

Downloads

Press release

Presentation

Q2 2023 Income statements

Q2 2023 net sales by GBU, franchise, geographic region and product

R&D appendix

Q2 2023 Memorandum for modelling purposes

Download infographic

Download infographic (accessible version)

Contact

Investor Relations

investor.relations@sanofi.com

More contact information